Overview / Abstract: |
Target Audience This activity is intended for physicians, physician assistants, nurse practitioners and registered nurses, pharmacists and psychologists engaged in the care of patients with schizophrenia. Program Overview Several novel and innovative therapies and therapeutic targets for schizophrenia are currently being investigated that are designed to target all, positive, or negative symptoms. This activity will focus on three main subject areas: unmet needs in the treatment of schizophrenia; innovative targets for drug discovery for schizophrenia; and current and emerging treatments for schizophrenia.The prevalence of insomnia changes throughout the lifespan, increasing after puberty, particularly in females, and continuing to increase throughout life. Although non-pharmacologic interventions are effective, patients often require pharmacologic interventions. In this program, we will discuss the latest developments in the treatment of insomnia in adolescent, adult geriatric, and dementia patients. Learning Objectives Upon completion of this activity, participants should be better able to: Discuss the unmet needs and treatment targets in schizophrenia |
Expiration |
Jan 20, 2022 |
Discipline(s) |
Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME, Psychology CE |
Format |
Online |
Credits / Hours |
1.0 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty FACULTY_NAME |
Sponsors / Supporters / Grant Providers |
Allergan, Eisai, Intra-Cellular Therapies, Jazz Pharmaceuticals, Neurocrine Biosciences, Sunovion, and Takeda. |
Keywords / Search Terms |
Relias LLC Relias LLC., FREE CME., Schizophrenia Free CE CME |